Sudeep Pharma IPO Details
The key details of Sudeep Pharma’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹895.00 Cr |
| Price Range | ₹563 - ₹593 |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII Quota | 15% |
| Employee Discount | -- |
| Listing at | NSE and BSE |
| Minimum Quantity | 25 |
| Investment (cut-off price) | ₹14,825 |
| Pre IPO Promotor Holding | 89.37% |
| Post IPO Promotor Holding | 76.15% |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Sudeep Pharma IPO Timelines
The IPO process for Sudeep Pharma includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
21/11/2025
Start Date25/11/2025
End Date27/11/2025
Refund Initiation27/11/2025
Credit of Shares to Demat Ac28/11/2025
Listing DateSudeep Pharma IPO Lot Size
The Sudeep Pharma IPO has a fixed lot size of 25 shares, at an upper price band of ₹593 per share. For retail investors, the minimum application is 25 shares (1 lot) amounting to ₹14,825, while the maximum is 325 shares (13 lots) worth ₹1,92,725. For Small HNI (S-HNI) investors, the minimum application is 350 shares (14 lots) worth ₹2,07,550, while the maximum is 1,675 shares (67 lots) amounting to ₹9,93,275. Big HNI (B-HNI) investors need to apply for at least 1,700 shares (68 lots), totaling ₹10,08,100.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 25 | ₹14,825 |
| Retail Maximum | 13 | 325 | ₹1,92,725 |
| S-HNI Minimum | 14 | 350 | ₹2,07,550 |
| S-HNI Maximum | 67 | 1675 | ₹9,93,275 |
| B-HNI Minimum | 68 | 1700 | ₹10,08,100 |
Sudeep Pharma IPO Subscription Status
The subscription status for Sudeep Pharma IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 0.09x | 3.01x | 1.53x | -- | 1.43x |
IPO Performance on Listing Day
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹ | ₹ | ₹ | ₹ |
Sudeep Pharma IPO Company Financials
Sudeep Pharma reports robust performance in FY2025 with Total Income of ₹511.33 crores, managing expenses at ₹328.48 crores, and achieving a strong PAT (Profit After Tax) of ₹138.69 crores, demonstrating significant growth potential ahead of its public offering.
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2023 | ₹438.26 | ₹352.28 | ₹62.32 |
| FY 2024 | ₹465.38 | ₹290.56 | ₹133.15 |
| FY 2025 | ₹511.33 | ₹328.48 | ₹138.69 |
| FY 2026 (3 M) | ₹130.08 | ₹86.00 | ₹31.27 |
About Company
Sudeep Pharma Limited, incorporated in 1989, is a global manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients, serving customers in more than 100 countries. Operating six manufacturing facilities with a combined capacity of 50,000 MT, the company specializes in a wide range of mineral-based products including calcium, iron, magnesium, zinc, potassium, and sodium. Its portfolio spans over 200 products catering to diverse sectors such as pharmaceuticals, food, and nutrition.
The company maintains robust R&D capabilities through in-house laboratories and pilot-scale facilities dedicated to advancing mineral salts and excipient technologies. Its business is structured across multiple segments, including Pharmaceutical, Food and Nutrition; Specialty Ingredients; and Triturates. As of December 31, 2024, Sudeep Pharma employed 704 permanent staff, supporting its operations and innovation-driven growth.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 1989 | Pharmaceuticals | Sujit Bhayani |
Know Before Investing
Sudeep Pharma IPO Strengths
- Sudeep Pharma is a leading manufacturer in the mineral-based excipients, specialty ingredients, and food nutrition industry, operating in regulated segments with high entry barriers.
- The company has invested in a dedicated R&D facility with over 40 personnel and has completed more than 420 R&D projects over the last three years, commercializing over 120 products.
- Their offers a wide range of pharmaceutical excipients, iron phosphates, encapsulated preservatives, and specialty ingredients used in pharma, food, and nutraceuticals.
- Sudeep Pharma’s plants are modern and compliant with global quality accreditations such as USFDA, EXCiPACT, FSSC, WHO-GMP, ISO, and HACCP.
- The company has posted consistent increases in revenue and profitability, with high and stable margins by global standards.
- Their serves blue-chip and Fortune 500 companies in developed and emerging markets, ensuring strong repeat business and credibility.
Sudeep Pharma IPO Risks
- A significant portion of sales comes from a limited group of customers, exposing the company to revenue loss if any major client reduces or stops orders.
- The business is exposed to strict global and domestic regulations for quality and certifications; any lapses can lead to operational shutdowns or export stoppages.
- The company is exposed to cost swings in chemicals and minerals that could squeeze margins in adverse cycles.
- Heavy export orientation exposes cash flows to currency fluctuation and global demand changes.
- Large, sophisticated customers may negotiate tighter contracts, affecting pricing and profitability.
- Faces intense competition from international giants in the specialty ingredient space, especially in regulated and developed markets.
Swot Analysis for Sudeep Pharma IPO
Strengths
Global Presence, Robust Manufacturing, High Customer Stickiness
Weaknesses
Customer Concentration, Raw Material Cost Risk, Capex Execution Challenges
Opportunities
Capacity Expansion, New Product Development, Geographic Diversification
Threats
Intense Competition, Export Exposure, Supply Chain Disruptions
Company Details
Sudeep Pharma Ltd.
129/1/A, GIDC Estate, Nandesari, Vadodara, Gujarat, 391340
Phone: +91 265 284 0656
Email: cs.sudeep@sudeepgroup.com
Website: https://www.sudeeppharma.com/
IPO Registar Details
MUFG Intime India Pvt. Ltd.
Phone: +91-22-4918 6270
Email: sudeeppharma.ipo@in.mpms.mufg.com
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
FAQs
The key objectives of Sudeep Pharma IPO are:
- Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I
- General corporate purposes
ICICI Securities Ltd. , IIFL Capital Services Ltd. are the book-running lead managers for the Sudeep Pharma IPO.
Sudeep Pharma IPO shows strong growth potential supported by rising global demand for specialty ingredients, planned capacity expansion of over 51200 MT by Q4FY26, and nearly 60 percent revenue contribution from exports. Its diversified portfolio, advanced R and D, and strong presence across regulated markets position it well for sustained expansion.
The issue price for the Sudeep Pharma IPO is set between ₹563 to ₹593 per share.
To invest in one lot of Sudeep Pharma IPO, you need ₹14,075 at the lower price band (₹563 per share) or ₹14,825 at the upper price band (₹593 per share) for a lot size of 25 shares.
Sudeep Pharma IPO shares are scheduled to be listed on both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on November 28, 2025.
Refund/unblocking of funds for Sudeep Pharma IPO will begin on November 27, 2025. ASBA/UPI blocks will be removed within 1 working day.
You can sell shares your Sudeep Pharma IPO shares on listing day (November 28, 2025) after they are credited to your demat account. If you want to sell in the pre-open market, the timing for that session is from 9:00 AM to 9:15 AM. Otherwise, you can sell after 10:00 AM during regular trading hours.